Headache: Edited by Peter GoadsbyCalcitonin gene-related peptide: an update on the biologyRecober, Anaa; Russo, Andrew FbAuthor Information aDepartments of Neurology, USA bMolecular Physiology and Biophysics, University of Iowa, Iowa City, Iowa, USA Correspondence to Ana Recober, MD, Associate, Department of Neurology, 2 RCP, 200 Hawkins Dr, University of Iowa, Iowa City, IA 52242, USA Tel: +1 319 335 7873; fax: +1 319 335 7330; e-mail: [email protected] Current Opinion in Neurology: June 2009 - Volume 22 - Issue 3 - p 241-246 doi: 10.1097/WCO.0b013e32832b2427 Buy Metrics Abstract Purpose of review This review includes the most relevant and recent studies on the biology of calcitonin gene-related peptide (CGRP) as it pertains to primary headaches and particularly to migraine. Especial attention was given to those published within the last year. Recent findings The development of CGRP receptor antagonists is discussed in detail, as well as recent advances in our understanding of CGRP actions in migraine. Finally, other important functions of CGRP outside of the nervous system are briefly discussed. Summary The advent of CGRP receptor antagonists as a novel therapy for migraine attacks may represent a new era in the acute management of migraine. More than a simple addition to the currently available treatments, this group of drugs may become an outstanding option for patients with cardiovascular disease, given the lack of associated vasoconstriction. Furthermore, nonpeptide CGRP receptor antagonists, CGRP antibodies and CGRP-binding RNA-Spiegelmer are valuable research tools that will further advance our understanding of migraine pathophysiology. © 2009 Lippincott Williams & Wilkins, Inc.